×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MYGN – myriad genetics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MYGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/24
01:30 pm
mygn
Tempus AI Stock Plunges 28.9% in Three Months: What's Next? [Yahoo! Finance]
Neutral
Report
Tempus AI Stock Plunges 28.9% in Three Months: What's Next? [Yahoo! Finance]
12/24
06:18 am
mygn
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price [Yahoo! Finance]
Medium
Report
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price [Yahoo! Finance]
12/20
09:22 am
mygn
MYGN Stock Might Gain From the New Recognition of RiskScore Study [Yahoo! Finance]
Low
Report
MYGN Stock Might Gain From the New Recognition of RiskScore Study [Yahoo! Finance]
12/19
04:32 pm
mygn
Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics [Yahoo! Finance]
Low
Report
Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics [Yahoo! Finance]
12/19
04:15 pm
mygn
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
Low
Report
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
12/17
07:32 am
mygn
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now? [Yahoo! Finance]
Low
Report
Is Myriad Genetics Stock a Smart Hold for Your Portfolio Right Now? [Yahoo! Finance]
12/13
11:16 am
mygn
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Bank of America Co. from $15.00 to $13.00. They now have an "underperform" rating on the stock.
Low
Report
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Bank of America Co. from $15.00 to $13.00. They now have an "underperform" rating on the stock.
12/10
06:26 pm
mygn
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
Medium
Report
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/12
04:19 pm
mygn
Form 4 MYRIAD GENETICS INC For: Dec 11 Filed by: Raha Samraat S.
Low
Report
Form 4 MYRIAD GENETICS INC For: Dec 11 Filed by: Raha Samraat S.
12/11
04:37 pm
mygn
Form 4 MYRIAD GENETICS INC For: Dec 10 Filed by: Davis Mark Steven
Low
Report
Form 4 MYRIAD GENETICS INC For: Dec 10 Filed by: Davis Mark Steven
12/10
04:52 pm
mygn
Form 3 MYRIAD GENETICS INC For: Dec 10 Filed by: Davis Mark Steven
Medium
Report
Form 3 MYRIAD GENETICS INC For: Dec 10 Filed by: Davis Mark Steven
12/10
04:09 pm
mygn
Form 8-K MYRIAD GENETICS INC For: Dec 10
Medium
Report
Form 8-K MYRIAD GENETICS INC For: Dec 10
12/2
04:17 pm
mygn
Form 4 MYRIAD GENETICS INC For: Nov 30 Filed by: Raha Samraat S.
Low
Report
Form 4 MYRIAD GENETICS INC For: Nov 30 Filed by: Raha Samraat S.
11/26
04:52 pm
mygn
Form 8-K MYRIAD GENETICS INC For: Nov 26
Low
Report
Form 8-K MYRIAD GENETICS INC For: Nov 26
11/14
04:17 pm
mygn
Form SC 13G/A MYRIAD GENETICS INC Filed by: GLENVIEW CAPITAL MANAGEMENT, LLC
Low
Report
Form SC 13G/A MYRIAD GENETICS INC Filed by: GLENVIEW CAPITAL MANAGEMENT, LLC
11/8
08:19 am
mygn
Form 10-Q MYRIAD GENETICS INC For: Sep 30
High
Report
Form 10-Q MYRIAD GENETICS INC For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/1
Form 8-K MYRIAD GENETICS INC For: Aug 01
55.0%
4/6 Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC 25.2%
3/23 Myriad Announces Board of Directors Leadership Transition 12.5%
11/6 GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions 11.5%
8/16 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.6%
12/4 Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening 7.9%
3/25 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 7.1%
8/2 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at Bank of America Corp from an "underperform" rating to a "neutral" rating. 6.8%
11/23 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm 6.4%
4/28 Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020 6.2%
4/6 Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC 25.2%
3/23 Myriad Announces Board of Directors Leadership Transition 12.5%
11/6 GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions 11.5%
8/16 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.6%
12/4 Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening 7.9%
3/25 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 7.1%
8/2 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at Bank of America Corp from an "underperform" rating to a "neutral" rating. 6.8%
11/23 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm 6.4%
4/28 Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020 6.2%
TOP News Decliners
8/13
Q4/2019 6/30/2019 EPS 0.410 ZacksConsensus 0.400 ActVsEst 0.010 - Beat
-42.8%
11/4 Q1/2020 9/30/2019 EPS 0.080 ZacksConsensus 0.260 ActVsEst (0.180) - Miss -40.1%
2/6 Q2/2020 12/31/2019 EPS 0.230 ZacksConsensus 0.220 ActVsEst 0.010 - Beat -28.2%
5/7 Form 8-K MYRIAD GENETICS INC For: May 07 -21.4%
8/14 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating. -9.9%
8/22 Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention -8.1%
6/14 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at Barclays PLC from $18.00 to $20.00. They now have an "underweight" rating on the stock. -7.7%
2/7 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from to . -6.3%
3/17 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.0%
8/7 Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer -4.6%
11/4 Q1/2020 9/30/2019 EPS 0.080 ZacksConsensus 0.260 ActVsEst (0.180) - Miss -40.1%
2/6 Q2/2020 12/31/2019 EPS 0.230 ZacksConsensus 0.220 ActVsEst 0.010 - Beat -28.2%
5/7 Form 8-K MYRIAD GENETICS INC For: May 07 -21.4%
8/14 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating. -9.9%
8/22 Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention -8.1%
6/14 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at Barclays PLC from $18.00 to $20.00. They now have an "underweight" rating on the stock. -7.7%
2/7 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from to . -6.3%
3/17 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.0%
8/7 Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: